
GB221 Gene Therapy Enters First-in-Human CHARISMA Trial for Spinal Muscular Atrophy Type 1
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQelNHdk16YTM1TFU2QjllaUd2dTBueDI0TUlCek10OHduRUMweUhsVlhOcTNmUEV2UGp0SVg2SHpYWXRxajRDcmVJbWdtUkVBWlBXMWZTUkkyRWc1YlVnUmxrMUhySTV2U1ZCSGpaeVZyVzF1MDhhR3BNUHZ6VWp6UGZYcllRclhtUHp5NW13T1hWQ2FjeGJOOWJqc3d2aXNJWlRzMFFWZUZTUzRieDktaWtsMXpIMy1CU1E?oc=5" target="_blank">GB221 Gene Therapy Enters First-in-Human CHARISMA Trial for Spinal Muscular Atrophy Type 1</a>&nbsp;&nbsp;<font color="#6f6f6f">NeurologyLive</font>